G
DESCRIPTION: The National Institutes of Health - NICHD intends to procure Exome and Taqman Quantitation Kits. The kits will be used for DNA analysis of samples collected from ongoing studies. This is the method used for previous samples and will allow the Lab to combine results of previous work.
This proposed procurement is for products and services for which the government intends to solicit and negotiate on a sole source basis to Life Technologies Corp. In order to comply with the requirements in this Solicitation/Special Note, the responses should be based on our interpretation of the general requirements provided below.
Special Note: The proposed contract action is for an Exome kits that would allow the sequencing services which the Lab has been performing in their research. It is also a continuation of previous services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302. Interested persons may identify their interest and capability to respond to the requirement and/or submit quotations. This notice of intent is not a request for competitive quotes. However, all quotes received within the time and date of publication of this "Special Notice" will be considered by the Government. A determination by the Government not to compete with this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a future competitive procurement.
HOW TO RESPOND: In order to compete for this project, interested parties must be registered in the Central Contracting Registration and submit a price quotation by 9 am, ET, July 1st, 2020. Offerors should submit one copy of the quote to MOE FILALI via email. Electronic transmissions to [email protected] are preferable but must be timely. It is the responsibility of the Offeror to ensure the proposal is received by the date and time shown above. All questions should be directed earlier..
Background and Lab’s Justification for specific Life Technologies’ Kits
“The aim of the project is to identify potentially clinically relevant genetic variants and it is therefore imperative that all subjects be screened using the same exome sequencing product to avoid the introduction of technical artifacts that can arise when different exome sequence enrichment products are utilized, which arise due to differences in the target regions enriched and due to differing enrichment profiles of common regions. Currently approximately 45% of the cohort have previously been sequenced using the AmpliSeq Exome product requested on the Ion Proton sequencers currently installed at the Laboratory of Neurogenesis. Different sequencer platforms have differing profiles for technical artifacts introduced by the sequencing chemistries, and differing abilities to detect variants, and so it is important that all subjects be sequenced using the same sequencing platform. “
The following Federal Acquisition Regulations clauses are incorporated by reference: FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Mar 2005), 52.212-4 (Sept 2005), 52.212-5, Contract Terms and Conditions Required to Implement Statutes of Executive Orders-Commercial Items (Aug 2006). (6)(i) 52.222-26, Equal Opportunity (Apr 2002) (E.O. 11246). (18) 52.222-35, Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (19) 52.222-36, Affirmative Action for Workers with Disabilities (Jun 1998) (29 U.S.C. 793). (20) 52.222-37, Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (31) 52.232-33, Payment by Electronic Funds Transfer-Central Contractor Registration (Oct 2003) (31 U.S.C. 3332).
Primary Point of Contact:
MOE FILALI Contracting Office Address:
NIH/NICHD Office of Acquisitions
6710B Rockledge Drive, Room 1145D
Bethesda, MD 20817
(w) 301.827 7737